

COMMONWEALTH OF PENNSYLVANIA	:	IN THE COURT OF COMMON PLEAS
BY JOSH SHAPIRO, in his official capacity	:	OF PHILADELPHIA COUNTY
as Attorney General of the Commonwealth of	:	
Pennsylvania,	:	
	:	FEBRUARY TERM, 2020
Plaintiff,	:	
	:	
v.	:	No. 200200962
	:	
JUUL LABS, INC.,	:	
	:	
Defendant.	:	
	:	

**Final Consent Judgment**

Plaintiff, the Commonwealth of Pennsylvania (the “Commonwealth” or “Pennsylvania”), commenced a civil investigation of Defendant JUUL Labs, Inc. (“JLI”) regarding potential violations of Pennsylvania’s Unfair Trade Practices and Consumer Protection Law, 73 P.S. § 201-1 et seq. and subsequently filed a Complaint against JLI, the resolution of which is the subject of this proposed Consent Judgment. The Parties stipulate that this Court may enter this Consent Judgment.

This Court has jurisdiction over the subject matter of this lawsuit and over all Parties. The terms of this Consent Judgment are governed by the laws of Pennsylvania. Entry of this Consent Judgment is in the public interest and reflects a negotiated agreement among the Parties. By entering into this Consent Judgment, the Parties have agreed to resolve the matters released as provided herein.

The Parties enter into this Consent Judgment without trial or adjudication of any contested issue of fact or law, and without finding or admission of wrongdoing or liability of any kind. JLI denies any wrongdoing and the allegations in the Complaint, and no part of this Consent Judgment, including its statements and commitments, shall constitute evidence of any

liability, fault, or wrongdoing by JLI. JLI is entering into this Consent Judgment solely for the purpose of concluding this matter, and nothing contained herein may be taken as or construed to be an admission or concession of any alleged violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or wrongdoing. This Consent Judgment shall not be construed or used as a waiver of any defense JLI may raise in any other proceeding.

Nothing in this Consent Judgment will be construed as an approval by the Attorney General, the Court, Pennsylvania, or any agency thereof of JLI's past, present, or future conduct. JLI shall not represent or imply that the Attorney General, the Court, Pennsylvania, or any agency thereof has approved or approves of any of JLI's actions or any of JLI's past, present, or future business practices.

## I. **DEFINITIONS**

1. As used herein:

- a. **"Adult-Only Facility"** means a facility or restricted area (whether open-air or enclosed) where the operator ensures or has a reasonable basis to believe (such as by checking identification as required under state law, or by checking the identification of any person appearing to be under the age of 30) that no Youth are present. A facility or restricted area need not be permanently restricted to persons over 21 years of age in order to constitute an Adult-Only Facility, provided that the operator ensures or has a reasonable basis to believe that no Youth are present during the event or time period in question.
- b. **"Attorney General"** means the Attorney General of Pennsylvania or any of its duly designated representatives.

- c. **“Brand Name”** means any product name, trademark, trade dress, logo, motto, or selling message used for any JUUL Products.
- d. **“Billboard”** means an individual advertisement that both (1) is placed outdoors or in an arena, stadium or shopping mall and (2) occupies an area larger than 70 square feet (or is placed in such proximity to any other such advertisement so as to create a single “mosaic”-type advertisement larger than 70 square feet); provided that “Billboard” does not include an advertisement on the outside (but on the property) of a JLI facility.
- e. **“Cartoon”** means any drawing or other depiction of an object, person, animal, creature, or any similar caricature that satisfies any of the following criteria: (1) the use of comically exaggerated features; (2) the attribution of human characteristics to animals, plants, or other objects, or the similar use of anthropomorphic technique; (3) the attribution of unnatural or extra-human abilities, such as imperviousness to pain or injury, X-ray vision, tunneling at very high speeds, or transformation; or (4) is presented in a non-realistic style.
- f. **“Claims”** means any and all civil (i.e., non-criminal) claims, demands, actions, suits, causes of action, damages, fines, penalties, and liabilities and monetary impositions of any nature, as well as costs, expenses, and attorneys’ fees, whether known or unknown, suspected or unsuspected, accrued or unaccrued, whether legal, equitable, statutory, regulatory, or administrative.
- g. **“Compliance Officer”** means the person appointed by JLI pursuant to

Paragraph 36.

- h. **“Covered Conduct”** means any and all of the following:
  - i. All conduct related to age verification, product quantity limits, nicotine content, flavors, or the size, shape, operation, or appearance of the product in the design, manufacture, marketing, advertising, product description, promotion, distribution, sale, or offer of JUUL Products.
  - ii. All conduct that could have induced a person, including a Youth, to use or purchase JUUL Products.
  - iii. All conduct that could have allowed a person, including a Youth, to use or purchase JUUL Products without allegedly adequate age verification, product quantity limits, or other age-based limitations or procedures.
  - iv. All conduct that may have violated federal, state, or local laws, regulations, or rules, or that could give rise to any common law cause of action, relating to the conduct described in subparagraphs (i)-(iii).
  - v. For the avoidance of doubt, Covered Conduct does not include any conduct relating to an undisclosed non-nicotine ingredient hazard in JUULpods resulting in personal injury to a consumer.
  - vi. As used herein, “conduct” includes, without limitation, any act, failure to act, practice, omission, statement, or representation.
- i. **“Effective Date”** means the date the Court enters the Consent Judgment.

- j. “**JLI**” means JUUL Labs, Inc. and its successors and assigns.
- k. “**JUUL Device**” means any electronic nicotine delivery system (“ENDS”) device sold, marketed, and/or distributed by JLI in the United States.
- l. “**JUULpod Packs**” means a package of JUULpods sold as one unit by JLI.
- m. “**JUULpods**” means any disposable pods sold, marketed, distributed, and/or manufactured by JLI and prefilled with a liquid solution containing nicotine that consumers use as part of the closed-pod, liquid-based, ENDS sold, marketed, and/or distributed by JLI in the United States.
- n. “**JUUL Product**” means any electronic nicotine delivery product sold, marketed, and/or distributed by JLI in the United States, including a closed-pod, liquid-based ENDS product composed of one or more of the following components: JUUL Device, JUULpods, JUULpod Packs, and/or a charger.
- o. “**Outdoor Advertising**” means (1) Billboards; (2) signs and placards in arenas, stadiums, and shopping malls; and (3) any other advertisements placed (A) outdoors, or (B) on the inside surface of a window facing outward; provided that “Outdoor Advertising” does not mean (1) an advertisement on the outside of a JLI facility; (2) an individual advertisement that does not occupy an area larger than 14 square feet (and that neither is placed in such proximity to any other such advertisement so as to create a single “mosaic”-type advertisement larger than 14 square feet, nor functions solely as a segment of a larger

advertising unit or series), and that is placed (A) on the outside of a Pennsylvania Retail Store, (B) outside (but on the property of) any such store, or (C) on the inside surface of a window facing outward in any such store; or (3) an advertisement inside a Pennsylvania Retail Store that sells JUUL Products that is not placed on the inside surface of a window facing outward.

- p. **“Parties”** or **“Party”** means Pennsylvania and JLI, collectively and individually, respectively.
- q. **“Pennsylvania Retail Store”** means a physical retail location in Pennsylvania that purchases JUUL Products either directly from JLI or from a JLI authorized distributor for resale directly to consumers.
- r. **“Released Parties”** means (1) JLI, (2) Pax and its successors and assigns, (3) their past and present direct or indirect subsidiaries and affiliates listed in Exhibit A (and their respective successors and assigns), and (4) each and all of the past and present principals, partners, officers, directors, supervisors, employees, stockholders and members, and insurers of any of the persons and entities listed in (1)-(3), but only to the extent that the person or entity was acting in such capacity on behalf of JLI.
- s. **“Releasers”** means (1) the Attorney General, and (2) only to the full extent of the Attorney General’s power and authority under Pennsylvania law to release Claims, Pennsylvania and any other Commonwealth entity or official or public or governmental entity or official within the

Commonwealth. “Releasers” does not include a person or entity otherwise within clause (2) if the Attorney General lacks power and authority under Pennsylvania law to release Claims of that person or entity as to the Claim at issue.

- t. **“Social Media Platform”** means any internet-based platform, including those which may be accessed through an app, through which users are able to create and/or share content that is accessible to members of the public, and includes, but is not limited to, sites such as Facebook, Instagram, Snapchat, TikTok, Twitter, Clubhouse, Pinterest, Tumblr, Google+, and YouTube.
- u. **“Verified”** means determined to be 21 years or older through the use of reliable and independent age-verification service(s) that cross-references the customer’s name, address, and date of birth against independent, competent, and reliable data sources, such as official government records. Specifically, “Verified” requires: (1)(a) that each customer submit a non-expired government identification, and (b) for the sale of JUUL Products only, that the billing address on the method of payment matches the shipping address for that order, or (2)(a) that the name, address, and date of birth provided by the customer are cross-referenced against information obtained from official government records or similar independent, competent, and reliable data sources, and (b) for the sale of JUUL Products only, that the last four digits of the customer’s Social Security Number is provided by the customer and is cross-referenced against

information obtained from official government records or similar independent, competent, and reliable data sources, a phone number or other personal indicator provided by the customer is used for two-factor authentication, and the billing address on the method of payment matches the shipping address for that order.

- v. “Youth” means individuals who are under the age of 21.

## **II. COMPLIANCE PROVISIONS**

### **Prohibition on Youth Targeting and Sales**

2. JLI shall not take any action, directly or indirectly, to target Youth within Pennsylvania in the advertising, promotion, or marketing of JUUL Products, or take any action the primary purpose of which is to initiate, maintain, or increase the incidence of Youth use of any JUUL Product within Pennsylvania.

3. JLI shall not (1) directly fund or operate any youth education campaigns or youth prevention activities in Pennsylvania, or (2) provide materials on youth education programs or events in Pennsylvania.

4. JLI shall not depict or portray any individual under the age of thirty-five (35) in any promotion, marketing, or advertising materials for JUUL Products in Pennsylvania.

5. JLI shall not use Cartoons in any of its promotion, advertising, or marketing for JUUL Products in Pennsylvania.

6. JLI shall not make any payment or provide other consideration to any person or entity in exchange for the placement of a JUUL Product or Brand Name displayed or accessible in any of the following in Pennsylvania: any motion picture, television show, theatrical production or other live performance, live or recorded performance of music,



commercial film or video, video game, including any of the foregoing displayed on any streaming media or website or that JLI has reason to believe would be shared on any Social Media Platform (collectively, "Media"). Provided, however, that the foregoing prohibition shall not apply to (a) Media where the audience or viewers are within an Adult-Only Facility (provided such Media are not visible to persons outside such Adult-Only Facility); (b) Media not intended for distribution or display to the public; or (c) instructional Media concerning how to use a JUUL Product viewed only by or provided only to persons who are not Youth. The prohibition in this Paragraph on product placement includes the prohibition on the use of any JUUL Product as a prop.

7. JLI shall not advertise, promote, market, distribute, offer, sell, license, or cause to be advertised, promoted, marketed, distributed, offered, sold, or licensed, any of the following that bears a Brand Name in Pennsylvania: any apparel, any other goods whose primary use is unrelated to the use or care of JUUL Products, or any item designed to be affixed to any such apparel or goods. Provided, however, that nothing in this subsection shall (a) require JLI to retrieve, collect or otherwise recover any item previously marketed, distributed, offered, sold, licensed, or caused to be marketed, distributed, offered, sold or licensed; (b) apply to apparel or other goods used solely within an Adult-Only Facility that is not distributed (by sale or otherwise) to any member of the general public; or (c) prohibit the distribution to any JLI employee who is not Youth of apparel or other goods that is intended for use in employment. For the avoidance of doubt, nothing in this Paragraph shall prevent JLI from the use of the Brand Name on any JUUL Product, the JUUL Device, accessories directly related to the use or care of the JUUL Device (including JUULpods, charger, and carrying case), or any other

nicotine related JLI products, or in any print or digital advertisements or coupons for any of the foregoing listed in this sentence.

8. JLI shall not advertise, market, promote, distribute, sell, offer, or otherwise provide any JUUL Product to any consumers, wholesalers, or Retail Stores in Pennsylvania in any flavor that JLI does not distribute or sell in Pennsylvania as of the Effective Date, unless and until JLI receives written FDA authorization that permits the marketing of that flavored JUUL Product.

9. JLI shall require any individual in Pennsylvania to be Verified at the first point of access to any website owned and/or operated by JLI before that consumer is able to access or view any content. Such first point of access may include a welcome page so long as it does not contain any information beyond the Brand Name and identification of the website. The requirements of this Paragraph are not applicable to JLI's corporate website currently available at [www.juullabs.com](http://www.juullabs.com) or [www.juullabsscience.com](http://www.juullabsscience.com) so long as such websites contain exclusively non-commercial content and, as to [www.juullabsscience.com](http://www.juullabsscience.com), JLI maintains the current attestation required on the welcome page.

### **Nicotine Content**

10. JLI shall not make any claims or representations in promotional, marketing, or advertising materials in Pennsylvania comparing the quantification of the amount of nicotine in JUUL Products to that found in combustible tobacco products or any other ENDS, unless JLI receives FDA authorization in writing that permits such claims or representations.

11. Beginning nine (9) months after the Effective Date, if JLI makes any statement about the nicotine content of JUUL Products in an advertisement or webpage, or promotional or marketing materials in Pennsylvania other than through the JUUL Product packaging or

label, JLI shall also disclose the amount of nicotine content in milligrams per milliliter (mg/ml) and as a percentage in terms of total volume of a JUULpod. This shall include any display of the nicotine content portion of the JUUL Product packaging or label in an advertisement, webpage, or promotional or marketing materials. The obligations under this Paragraph are no longer in effect if (1) the FDA implements a uniform nicotine content disclosure standard for ENDS products or (2) JLI receives written FDA authorization for JUUL Products that permits JLI to use a specific nicotine content disclosure.

### **Sponsorships and Naming Rights**

12. JLI shall not sponsor any events in Pennsylvania in which payment is made (or other consideration is provided) in exchange for use of any Brand Name.

13. Notwithstanding Paragraph 12, JLI may sponsor events in Pennsylvania:

- a. At an Adult-Only Facility, or
- b. In the name of JLI's corporate name, provided that the sponsorship uses the abbreviation "JLI" for the corporate name, does not use the word "JUUL," and does not include reference to JUUL Products.

### **Advertising and Marketing**

14. JLI shall not advertise, market, or promote JUUL Products in media or outlets in Pennsylvania unless, according to nationally established advertising demographic services, such as Comscore, 85% or more of the individuals comprising the audience of the media or outlets are not Youth. This provision does not apply to marketing or advertising through Outdoor Advertising, on the property of Pennsylvania Retail Stores selling JUUL Products, or on any online website that requires Pennsylvania consumers to be Verified before being able to further access the website.

15. JLI shall not use Billboards in Pennsylvania. JLI shall not place or cause to be placed Outdoor Advertising at any location in Pennsylvania that at the time of the placement, or renewal of the placement, of the Outdoor Advertising is within 1,000 feet of any elementary, middle, or high school or public playground in Pennsylvania.

16. JLI shall not place or cause to be placed any marketing or advertising in or on public transportation or inside public transportation facilities in Pennsylvania, including, but not limited to, taxicabs, public buses or bus stations, public trains or train stations, and airports. This Paragraph shall not apply to any in-store materials at any Pennsylvania Retail Store located in a public transportation facility or any material in a designated smoking area within any public transportation facility.

17. JLI shall not publish any marketing, promotional, or advertising material for JUUL Products on any Social Media Platform accessible in Pennsylvania, provided that JLI shall be permitted to use Twitter, LinkedIn, and YouTube for (i) hosting testimonial videos of the experiences of persons thirty-five (35) years of age or older who are or were habitual combustible cigarette smokers using JUUL Products, and (ii) non-promotional communications. JLI shall not use any testimonials or other advertising, promotional, or marketing material in Pennsylvania that makes a claim or representation that JUUL Products or vaping is safer than combustible cigarettes, are modified risk products, or are smoking cessation devices prior to such claim or representation (or the substance thereof) being allowed by federal authorities.

18. JLI shall not create or use any hashtags in Pennsylvania for the purpose of advertising, marketing, or promoting any JUUL Product.

19. JLI shall not engage or pay any person or entity, through payment or other consideration (including non-monetary consideration or discounted or free product), to advertise, market, or promote JUUL Products on any Social Media Platform accessible in Pennsylvania.

20. JLI shall not engage or pay any person or entity, through payment or other consideration (including non-monetary consideration or discounted or free product), to promote JUUL Products in person in Pennsylvania, unless the operator of the location or event represents through a contract with JLI that, in connection with such promotion, it shall undertake reasonable industry standard measures to prohibit access by Youth.

21. JLI shall not send direct-to-consumer advertising, promotional, or marketing emails, materials, or text messages for JUUL Products to any Pennsylvania consumers who are not Verified.

### **Samples**

22. JLI shall not provide free JUUL Products to Pennsylvania consumers.

### **Sales and Distribution Restrictions**

23. JLI shall not expressly authorize or otherwise enter into any agreement with any Pennsylvania Retail Store to (1) display unsecured JUUL Products in a location other than behind a counter or (2) allow individuals to access JUUL Products without the assistance of a Pennsylvania Retail Store employee. If the Attorney General notifies JLI or JLI customer service is notified in writing that any Pennsylvania Retail Store is engaging in any activity that JLI is not permitted to authorize in this Paragraph, JLI shall promptly take commercially reasonable steps to investigate and halt any such activity.

24. JLI shall limit online sales to Pennsylvania consumers of JUUL Products on any website owned and/or operated by JLI to no more than two (2) JUUL Devices per month, ten (10) JUUL Devices per calendar year, and sixty (60) JUULpods per month, sold individually or through JUULpod Packs.

25. JLI shall take reasonable steps to limit retail transactions at Retail Stores in Pennsylvania to one (1) JUUL Device and/or sixteen (16) JUULpods, sold individually or through JUULpod Packs, per transaction, including (a) requiring that any contract it enters with a Pennsylvania Retail Store for the purchase or sale of JUUL Products provide that the Pennsylvania Retail Store shall comply with such limits and (b) continuing to maintain the bulk sale limits in the JUUL Labs Authorized Reseller Program Policy. JLI shall continue to assess compliance through JLI Compliance Checks as described in Paragraph 37 below.

26. JLI shall not offer, sell, deliver, or in any manner directly provide any JUUL Products to Pennsylvania consumers who have not been Verified.

27. In furtherance of Paragraph 26, for all sales of JUUL Products to Pennsylvania consumers on any website owned and/or operated by JLI, JLI shall continue to recommend to credit card companies (through JLI's third-party payment gateways or processors) that the words "JUUL TOBACCO PRODUCT" be printed on the consumer's credit card statement or such other language as may be required by Pennsylvania law or regulation.

28. Prior to distributing JUUL Products to Pennsylvania consumers through a consumer warranty program, JLI shall first confirm that the individual requesting the warranty replacement is Verified.

29. Prior to enrolling Pennsylvania consumers in any auto-shipment program, JLI shall first confirm that the individual to be enrolled in the auto-shipment program is Verified.

30. If JLI is provided notice in writing pursuant to this Consent Judgment by the Pennsylvania Department of Health or Pennsylvania Office of Attorney General that a JUUL Product previously purchased by a consumer through an online sale is later provided to a Youth, JLI shall not knowingly sell JUUL Products on any website owned and/or operated by JLI to that Pennsylvania purchasing consumer.

31. JLI shall not license or expressly authorize any third party to engage in conduct that is impermissible under the terms of this Consent Judgment if done directly by JLI.

32. JLI shall continue to monitor Social Media Platforms and third-party websites in the United States that resell JUUL Products to identify content promoting use of JUUL Products by Youth, unauthorized sales of JUUL Products, or content that would otherwise be impermissible by JLI under this Consent Judgment.

33. JLI shall continue to use reasonable efforts, including possible legal action, to work with Social Media Platforms and owners of third-party websites in the United States that resell JUUL Products to remove content promoting use of JUUL Products by Youth, unauthorized sales of JUUL Products, or content that would otherwise be impermissible by JLI under this Consent Judgment.

34. The Parties agree that JLI shall be deemed to be in compliance with Paragraph 33 if it continues to (i) engage a nationally recognized service provider to monitor Social Media Platforms and third-party websites in the United States that resell JUUL Products using the service provider's "web-scraping" or similar technology for effective monitoring, and (ii) maintain a process for diligently requesting that Social Media Platforms or owners of third-party websites in the United States that resell JUUL Products remove the content identified

through such monitoring. JLI may follow any procedures that Social Media Platforms or websites have established for providing notice of the content.

35. The Parties agree that compliance with Paragraphs 33-34 does not create any liability for JLI for content posted by a third party or for the failure of a third party to remove posted content after being requested by JLI. JLI shall maintain records sufficient to document its compliance with Paragraphs 33-34.

### **Retail Compliance**

36. JLI shall designate and maintain a Compliance Officer, who shall be a corporate senior-level employee responsible for ensuring compliance with this Consent Judgment and shall act as a point of contact with Pennsylvania to address any compliance-related issues.

37. JLI shall maintain a retailer-compliance program for Pennsylvania Retail Stores that requires:

- a. JLI to send representatives to conduct unannounced JLI Compliance Checks at 188 Pennsylvania Retail Stores per year for two (2) years after the Effective Date. A “JLI Compliance Check” is an assessment of a Pennsylvania Retail Store’s compliance with the (a) federal requirements to verify a purchaser’s age pursuant to 21 C.F.R. § 1140.14 or (b) product-quantity limits of up to one (1) JUUL Device and sixteen (16) JUULpods, sold individually or through JUULpod Packs, per transaction, or both.
- b. JLI to use reasonable efforts to have the representatives conduct JLI Compliance Checks at different Pennsylvania Retail Stores each month. JLI to use reasonable efforts to have the Compliance Checks conducted by service providers engaged by JLI.



- c. The representative conducting the JLI Compliance Check to complete a standardized form documenting the transaction(s) in which he or she participated in each store, which shall note any violations. The representative's compensation shall not be dependent on the results of the retailer-compliance inspections.
- d. JLI to implement the following penalties to Pennsylvania Retail Stores for violations of the JLI Compliance Checks:
  - i. First JLI Compliance Check Failure: JLI shall issue a letter notifying the Pennsylvania Retail Store of its first violation. The letter shall reiterate the requirements of the JLI Compliance Checks and the penalty escalation structure. For any Pennsylvania Retail Store that commits a first violation, JLI shall perform a second JLI Compliance Check within ninety (90) days of the first violation, which shall be in addition to the above-stated annual requirement.
  - ii. Second JLI Compliance Check Failure: If a second violation occurs within one year of the first violation, JLI shall issue a letter notifying the Pennsylvania Retail Store of the second violation. JLI shall suspend (or shall instruct any wholesaler, distributor, or sub-distributor through which JLI supplies the Pennsylvania Retail Store to suspend) the Pennsylvania Retail Store from any promotional activities for six months following the date of the second failed JLI Compliance Check. For any Pennsylvania Retail Store that commits a second violation, JLI shall perform a third JLI

Compliance Check within ninety (90) days of the second violation, which shall be in addition to the above-stated annual requirement. For any second age-verification failure, JLI shall communicate the age-verification non-compliance to the United States Food and Drug Administration (“FDA”).

- iii. Third JLI Compliance Check Failure: If a third violation occurs within one year of the first violation, JLI shall issue a letter notifying the Pennsylvania Retail Store of the third violation. JLI shall cease doing business with the Pennsylvania Retail Store as an authorized retailer for three (3) years from the date of the third failed JLI Compliance Check, and notify all applicable wholesalers, distributors, and sub-distributors to suspend sales of JUUL Products to the Pennsylvania Retail Store for the three-year period. For any Pennsylvania Retail Store that commits a third violation, JLI shall perform a fourth JLI Compliance Check within ninety (90) days of the third violation, which shall be in addition to the above-stated annual requirement. For any third age-verification failure, JLI shall communicate the age-verification non-compliance to the FDA.
- iv. Fourth JLI Compliance Check Failure: If a fourth violation occurs within one year of the first violation, JLI shall cease doing business with the Pennsylvania Retail Store and notify all applicable wholesalers, distributors, and sub-distributors to suspend sales of JUUL Products to the Pennsylvania Retail Store. The embargo on

doing business with that Pennsylvania Retail Store shall remain in place until new ownership of that Pennsylvania Retail Store wholly unrelated to the embargoed ownership is in place and licensed to sell vapor products. Where that Pennsylvania Retail Store is part of a chain or similar group of stores, “ownership” in the preceding sentence shall refer to the owner or franchisee of the specific Pennsylvania Retail Store at issue, and not to a parent company or owner of the chain. For any fourth age-verification failure, JLI shall communicate the age-verification non-compliance to the FDA.

- v. Nothing in this Paragraph requires JLI to breach any existing contractual obligations with wholesalers, distributors, or sub-distributors.
- e. If (i) JLI receives information pursuant to this Paragraph or (ii) JLI customer service receives information or complaints of Pennsylvania Retail Stores violating the age-verification requirements or product quantity limits, JLI shall conduct a JLI Compliance Check of those retail stores within ninety (90) days of receipt of such information or complaints.
- f. JLI’s obligations under this Paragraph become effective on the first day of the first full calendar month beginning no earlier than twenty-one (21) days after the Effective Date.
- g. Every six (6) months, JLI shall provide the Pennsylvania Department of Health and Pennsylvania Office of Attorney General with results of its JLI Compliance Checks of Pennsylvania Retail Stores, with the first set of

results being provided six months and two weeks after the terms of this Paragraph become effective pursuant to Paragraph 37(f).

38. The Parties agree that JLI shall not be subject to any liability for any conduct by Pennsylvania Retail Stores arising out of or relating to JLI's creation and maintenance of the retailer-compliance program described above.

39. JLI shall continue to include serial numbers on JUUL Devices that permit Pennsylvania's consumers to report the serial number of a JUUL Device confiscated from a Youth through a website, currently <https://www.juul.com/trackandtrace>. Every six (6) months with the reports provided pursuant to Paragraph 37(g), JLI shall report to the Pennsylvania Department of Health and Pennsylvania Office of Attorney General any and all information regarding any submissions to the website for transactions identified as relating to a Pennsylvania Retail Store.

### **III. MONETARY PAYMENT**

40. Subject to the terms and conditions below and the additional amount specified in paragraph 41, JLI shall pay the amount of \$35,880,935 to Pennsylvania as follows: (a) \$3,384,994 by December 31, 2022 or the Effective Date, whichever is later, (b) annual payments of \$3,384,994 by December 31, 2023 and December 31, 2024 or the Effective Date, whichever is later, (c) annual payments of \$5,077,491 by December 31, 2025 and December 31, 2026, and (d) a final payment of \$15,570,971 by December 31, 2027. In lieu of the final payment of \$15,570,971 set out in the previous sentence, JLI may elect to either: (1) make annual payments of \$5,707,099 by December 31, 2027, December 31, 2028, and December 31, 2029; or (2) make annual payments of \$3,737,033 by December 31, 2027, December 31,

2028, December 31, 2029, December 31, 2030, and December 31, 2031. JLI shall specify its election by November 30, 2027.

41. JLI shall also pay, within thirty (30) days of the Effective Date, an amount of \$3,000,000.00 directed to the “Commonwealth of Pennsylvania Office of Attorney General” to reimburse the Office of Attorney General for its attorneys’ fees and costs and to provide for future costs for enforcement work to be performed by the Public Protection Division, and to reimburse the National Association of Attorneys General for Pennsylvania’s share of Tobacco Enforcement Fund grants utilized to pay expert witness fees and costs, deposition costs, and Everlaw Document Review platform costs related to the Office of Attorney General’s litigation with JLI.

42. Failure to make a payment within 14 days of the due date is a default on JLI’s payment obligations with respect to Pennsylvania under this Consent Judgment. Should JLI default on any payment obligation imposed by this Consent Judgment, in addition to any other penalties and remedies provided by law, all payments set forth herein will be accelerated and become due and owing in their entirety as of the date of the default, with interest accruing thereon at the prime rate, for the full amount owing as of that date. Pennsylvania shall provide JLI a notice of default and the amount owing, and JLI shall have 30 days from the date of that notice to remit payment to avoid the acceleration referenced above.

43. The amounts paid to Pennsylvania under Paragraph 40 constitute compensatory restitution and remediation (within the meaning of 26 U.S.C. § 162(f)(2)(A)) and are intended to restore, in whole or in part, Pennsylvania to the same condition or position it would have been in had it not suffered the harms alleged to have been caused by JLI’s actions alleged in the Complaint, and such amounts are no greater than such alleged harms.

44. The amounts paid to Pennsylvania under Paragraph 40 shall be paid to the Pennsylvania Department of Health and used to the maximum extent possible by the Pennsylvania Department of Health, Bureau of Health Promotion and Risk Reduction, to fund programs aimed at remediating the harms alleged to have been caused by JLI's actions alleged in the Complaint. This will include programs to reduce or eliminate tobacco-related death and disease in the Commonwealth through innovation, utilization of resources, and promotion of smoke-free environments and tobacco-free lifestyles. This shall include but is not limited to: development, implementation, and supporting strategic and culturally appropriate efforts to reduce tobacco product use and exposure to secondhand smoke in Pennsylvania to enhance the quality of life for all residents. In addition, funds shall be used to prevent initiation of tobacco use among youth and young adults, promote tobacco use cessation among adults and youth, eliminate exposure to secondhand smoke, identify and eliminate tobacco-related disparities, and other such matters as are reasonably aimed at remediating the harms alleged in the Complaint and deemed appropriate and necessary by the Department.

45. The Parties agree that no portion of the amounts to be paid to Pennsylvania under Paragraph 40 (i) represents reimbursement to Pennsylvania for the costs of any investigation or litigation, (ii) is in lieu of any fine or penalty, or (iii) is properly characterized as disgorgement or the payment of statutory or other fines, penalties, punitive damages, or other punitive assessments.

46. Pennsylvania shall cause to be completed and timely filed a Form 1098-F with the Internal Revenue Service that identifies the amounts to be paid under Paragraph 40 as "remediation/restitution," and shall timely furnish Copy B of such Form 1098-F (or an acceptable substitute statement) to JLI.

**IV. NOTICE**

47. All notices or certifications required to be provided to a Party or a designated state office shall be sent electronically and by first class mail, postage pre-paid, as follows, unless a Party gives notice of a change to the other Party:

a. For JLI:

Tyler Mace  
Chief Legal Officer  
JUUL Labs, Inc.  
1000 F Street  
Washington, D.C. 20004  
tyler.mace@juul.com

*With a copy to:*

JB Kelly  
Wachtell, Lipton, Rosen & Katz  
51 West 52<sup>nd</sup> Street  
New York, NY 10019  
jbkelly@wlrk.com

b. For Pennsylvania/Pennsylvania Office of Attorney General:

Edmund "Tad" Berger  
Chief Deputy Attorney General  
Pennsylvania Office of Attorney General  
Tobacco Enforcement Section  
Strawberry Square, 15<sup>th</sup> Floor  
Harrisburg, PA 17120  
tobacco@attorneygeneral.gov

c. For Pennsylvania Department of Health:

Kevin Hoffman, Esquire  
Pennsylvania Department of Health  
Office of Legal Counsel  
Room 825 | Health and Welfare Building  
625 Forster Street | Harrisburg, PA 17120  
Ph: 717-783-2500 | Fax: 717-705-6042  
www.health.pa.gov

## **V. ENFORCEMENT**

48. JLI shall, after diligent inquiry, annually certify compliance with this Consent Judgment to the Pennsylvania Department of Health pursuant to the notice provisions in Section IV.

49. For the purposes of resolving disputes with respect to compliance with the injunctive terms of this Consent Judgment, should Pennsylvania have a reasonable basis to believe that JLI has engaged in a practice that may have violated the terms of this Consent Judgment, Pennsylvania shall notify JLI in writing of the specific objection, identify with particularity the provision of this Consent Judgment that the practice appears to violate, and give JLI thirty (30) days to respond to the notification. JLI shall have the thirty (30) day period to provide a good faith written response to Pennsylvania's notification, containing either a statement explaining why JLI believes it is in compliance with the Consent Judgment or a detailed explanation of how the alleged violation occurred and a statement explaining how JLI intends to remedy the alleged breach. Following receipt of JLI's written response, the parties shall meet and confer in good faith regarding the alleged violation. Nothing in this Section limits Pennsylvania's Civil Investigative Demand ("CID") or investigative subpoena authority, and JLI reserves all of its rights in responding to a CID or investigative subpoena issued pursuant to such authority.

50. Pennsylvania may assert any claim that JLI has violated this Consent Judgment in a separate civil action to enforce compliance with this Consent Judgment, or may seek any other relief afforded by law for violations of the Consent Judgment, but only after providing JLI an opportunity to respond to the notification described in Paragraph 47 above; provided,



however, that Pennsylvania may take any action if Pennsylvania believes that, because of the specific practice, a threat to the health or safety of the public requires immediate action.

## **VI. RELEASE**

51. Releasors hereby release and forever discharge the Released Parties from any and all Claims based on, arising out of, or in any way related to the Covered Conduct prior to the Effective Date to the full extent of the Attorney General's power and authority to release Claims (the "Released Claims").

52. The release in Paragraph 51 is intended by the Parties to be broad and shall be interpreted so as to give the Released Parties the broadest possible bar against any liability relating in any way to Released Claims. This Consent Judgment shall be a complete bar to any Released Claims.

53. Notwithstanding any term of this Consent Judgment, any and all of the following forms of liability are specifically reserved and not released under Paragraph 51:

- a. Any criminal liability;
- b. Any liability for state or federal securities violations;
- c. Any liability for state or federal tax violations;
- d. Any state or federal antitrust liability;
- e. Any state or federal environmental liability; and
- f. Any enforcement of the terms of this Consent Judgment.

## **VII. PARITY PROVISION**

54. If, after the Effective Date, but before the date four (4) years after such date, JLI enters into any pre-trial and pre-judgment settlement or consent judgment with another state, commonwealth, or territory of the United States or the District of Columbia, by and through

their attorneys general (“Other State(s)”), that resolves claims similar to the Released Claims, and such settlement or consent judgment contains overall compliance provisions more favorable to such Other State than the overall compliance terms of this Consent Judgment, then this Consent Judgment will be revised to contain such more favorable compliance provisions.

55. If JLI enters into a pre-trial or pre-judgment settlement or consent judgment with an Other State during the time period referenced in Paragraph 54, JLI shall provide a copy of such Other State’s settlement document to Pennsylvania for review within ten (10) days of its effective date. If, after review of the Other State’s settlement document, Pennsylvania believes such settlement document contains overall conduct terms requiring revision to this Consent Judgment, then, Pennsylvania shall provide written notice to JLI within 15 days of receipt of the Other State’s settlement document requesting that this Consent Judgment be revised to contain such more favorable conduct terms. JLI and Pennsylvania shall promptly meet and confer in good faith concerning any such request. If an agreement is reached between JLI and Pennsylvania that a revision of this Consent Judgment is required, this Consent Judgment shall be revised accordingly. If an agreement is reached between JLI and Pennsylvania that no revision of this Consent Judgment is required, then this Consent Judgment shall not be revised. If after meeting and conferring JLI and Pennsylvania fail to reach an agreement as to

whether a revision is required, the Attorney General of Pennsylvania may request that the Court determine whether revision of this Consent Judgment is required under this Paragraph.

**VIII. GENERAL TERMS**

56. Term: The provisions of Paragraphs 2-39 shall remain in place as follows:

- a. The provisions of Paragraphs 2, 3, 4, 5, 15, 19, and 21, and the provisions of Paragraph 31 to the extent the underlying terms at issue have not expired under this Paragraph, shall not expire (subject to the provisions of subparagraph c below).
- b. The provisions of Paragraphs 8, 10, and 11, shall not expire except as described in those provisions.
- c. The remaining provisions shall expire six (6) years after the Effective Date. If JLI receives an Authorization Order that contains authorizations, obligations, standards, or requirements as to conduct addressed in a provision of Section II (including by incorporating actions, obligations, standards, requirements proposed or set forth in JLI's application for such Authorization Order), then as of the date of such Authorization Order:
  - i. such authorizations, obligations, standards, or requirements shall supersede any different obligations, standards, or requirements in Section II of this Consent Judgment; and
  - ii. actions by JLI that act within or reasonably implement such obligations, standards or requirements of the Authorization Order shall be permissible under this Consent Judgment even if any provision hereof would provide otherwise.

d. "Authorization Order" means a granted written marketing order from the FDA authorizing a Premarket Tobacco Product Application ("PMTA") submitted by JLI related to JUUL Products or other written authorization from the FDA to JLI related to JUUL Products (including a Modified Risk Tobacco Product Application).

57. Pennsylvania will not take the position that any generally applicable law or regulation requires conduct by JLI different than the conduct Pennsylvania requires from any other manufacturer or seller of ENDS products.

58. Nothing in Paragraphs 56-57 will be construed as an approval by the Pennsylvania Attorney General, the Court, Pennsylvania, or any agency thereof of Defendant's past, present, or future conduct or business practices.

59. Applicability: This Consent Judgment applies only to JLI in its corporate capacity and acting through its respective successors and assigns, directors, officers, employees, agents, subsidiaries, divisions, or other internal organizational units of any kind or any other entities acting in concert or participation with them. The remedies, penalties, and sanctions that may be imposed or assessed in connection with a violation of this Consent Judgment (or any order issued in connection herewith) shall only apply to JLI.

60. Successors: This Consent Judgment is binding on, and inures to the benefit of, the Parties' successors and assigns. For the avoidance of doubt, if JLI ceases selling a type of JUUL Product that it either sold in the United States or had in development as of either April 1, 2022 or the Effective Date, and a company other than JLI thereafter sells such type of JUUL Product in Pennsylvania, that company shall be considered a successor of JLI with respect to such JUUL Product for purposes of compliance provisions under Section II of this Consent

Judgment and all associated provisions necessary for their enforcement and interpretation. For the avoidance of doubt, the compliance provisions of Section II of this Consent Judgment shall not apply to such company's own products.

61. Denial and No Admission: JLI denies it and/or its employees, officers, directors, subsidiaries, founders, and/or owners have violated any statute, regulation, decision, or other source of law. The Parties are entering into this Consent Judgment for the purpose of compromising and to avoid the time, expense, burden, and uncertainty associated with continuing litigation, and to address Pennsylvania's concerns with JLI's historical business practices with respect to JUUL Products. It is expressly agreed that this Consent Judgment is not admissible in any proceeding (except in a dispute between Pennsylvania and JLI regarding compliance with the Consent Judgment or as necessary for the Released Parties to enforce the release provisions), and it is also expressly agreed and understood that nothing contained in this Consent Judgment may be taken as or construed to be an admission or concession of any liability, wrongdoing, or violation of any source of law, or of any other matter of fact or law. This Consent Judgment is not intended to be used or admissible in any unrelated administrative, civil, or criminal proceeding. JLI does not waive any defenses it may raise elsewhere in other litigation or matters.

62. Private Action: This Consent Judgment shall not confer any rights upon, and is not enforceable by, any persons or entities besides Pennsylvania and the Released Parties. Pennsylvania may not assign or otherwise convey any right to enforce any provision of this Consent Judgment, provided that nothing in this sentence shall preclude Pennsylvania from employing the services of a collection agency for the purpose of pursuing collection of payments due under this Consent Judgment.

63. Conflict with Other Laws: Nothing in this Consent Judgment shall impose an obligation on JLI that conflicts with JLI's obligations under federal, state, or local law, rule, regulation, or guidance. In the event there is a conflict between this Consent Judgment and the requirements of federal, state, or local laws, such that JLI cannot comply with this Consent Judgment without violating these requirements, JLI shall document such conflicts and notify Pennsylvania that it intends to comply with the federal, state, or local requirements to the extent necessary to eliminate the conflict. Within thirty (30) days after receipt of a notification from JLI referenced above, Pennsylvania may request a meeting to discuss the steps JLI has implemented to resolve the conflict, and JLI shall comply with any such reasonable request.

64. The marketing, advertising, or sale of JUUL Products intended solely for consumers outside Pennsylvania shall not be deemed actions taken (or omitted to be taken) in Pennsylvania or directed at consumers in Pennsylvania, and the provisions of this Consent Judgment shall not be applicable to such marketing, advertising, or sale of JUUL Products.

65. Nothing in this Consent Judgment shall prohibit JLI from complying with the terms of any court order.

66. Except as expressly set forth herein, this Consent Judgment shall not be modified (by this Court, by any other court, or by any other means) without the consent of Pennsylvania and JLI, or as provided for in Paragraphs 54-55.

67. This Consent Judgment shall not be construed or used as a waiver or any limitation of any defense otherwise available to JLI in any pending or future legal, regulatory, or administrative action or proceeding, or JLI's right to defend itself from, or make any arguments in, any individual or class claims or suits.

68. Except for Paragraphs 51-53, if any provision of this Consent Judgment shall, for any reason, be held illegal, invalid, or unenforceable, in whole or in part, such illegality, invalidity, or unenforceability shall not affect any other provision or clause of this Consent Judgment and this Consent Judgment shall be construed and enforced as if such illegal, invalid, or unenforceable provision, in whole or in part, had not been contained herein.

69. This Consent Judgment represents the entire agreement between the Parties, and there are no representations, agreements, arrangements, or understandings, oral or written, between the Parties relating to the subject matter of this Consent Judgment that are not fully expressed herein or attached hereto. In any action undertaken by the Parties, no prior versions of this Consent Judgment and no prior versions of any of its terms that were not entered by the Court in this Consent Judgment may be introduced for any purpose whatsoever.

70. The Court retains jurisdiction over this Consent Judgment and the Parties with respect to this Consent Judgment.

71. This Consent Judgment does not limit the rights of any private party to pursue any private remedies allowed by law; provided that this Consent Judgment is not intended to create any private right of action by other parties.

72. This Consent Judgment may be executed by the Parties in counterparts and be delivered by facsimile or electronic transmission, or a copy thereof, such constituting an original counterpart hereof, all of which together will constitute one and the same document.

Dated: December 8, 2022

Respectfully submitted,



---

Joseph S. Swartz (ID No. 314878)  
Deputy Attorney General

FOR: JOSH SHAPIRO  
ATTORNEY GENERAL

Michelle A. Henry  
First Deputy Attorney General

James A. Donahue, III  
Executive Deputy Attorney General

Edmund J. Berger  
Chief Deputy Attorney General

Office of Attorney General  
Strawberry Square, 15<sup>th</sup> Floor  
Tobacco Enforcement Section  
Harrisburg, PA 17120  
717-783-1794

*Attorneys for the  
Commonwealth of Pennsylvania*

On behalf of JUUL Labs, Inc.:

---

Scott Richburg  
Senior Vice President, Head of Litigation

*/s/ Will W. Sachse*  
Will W. Sachse (ID No. 84097)  
DECHERT LLP  
Cira Centre  
2929 Arch Street  
Philadelphia, PA 19104-2808  
Tel: (215) 994-2496

Renee D. Smith  
KIRKLAND & ELLIS LLP  
300 North LaSalle  
Chicago, IL 60654  
Tel: (312) 862-2000

Peter A. Farrell, P.C.  
Katherine R. Katz  
KIRKLAND & ELLIS LLP  
1301 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel: (202) 389-5000

*Attorneys for Juul Labs, Inc.*



Dated: December 8, 2022

Respectfully submitted,

---

Joseph S. Swartz (ID No. 314878)  
Deputy Attorney General

FOR: JOSH SHAPIRO  
ATTORNEY GENERAL

Michelle A. Henry  
First Deputy Attorney General

James A. Donahue, III  
Executive Deputy Attorney General

Edmund J. Berger  
Chief Deputy Attorney General

Office of Attorney General  
Strawberry Square, 15<sup>th</sup> Floor  
Tobacco Enforcement Section  
Harrisburg, PA 17120  
717-783-1794

*Attorneys for the  
Commonwealth of Pennsylvania*

On behalf of JUUL Labs, Inc.:



---

Scott Richburg  
Senior Vice President, Head of Litigation

/s/ Will W. Sachse  
Will W. Sachse (ID No. 84097)  
DECHERT LLP  
Cira Centre  
2929 Arch Street  
Philadelphia, PA 19104-2808  
Tel: (215) 994-2496

Renee D. Smith  
KIRKLAND & ELLIS LLP  
300 North LaSalle  
Chicago, IL 60654  
Tel: (312) 862-2000

Peter A. Farrell, P.C.  
Katherine R. Katz  
KIRKLAND & ELLIS LLP  
1301 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel: (202) 389-5000

*Attorneys for Juul Labs, Inc.*

## Exhibit A

1. JUUL Labs, Inc., a corporation organized under the laws of Delaware.
2. 1186610 B.C. Ltd., a limited liability company organized under the laws of the Province of British Columbia.
3. 1186675 B.C. Ltd., a limited liability company organized under the laws of the Province of British Columbia.
4. Ala Kupono Insurance, Co. Inc. a corporation organized under the laws of Hawaii.
5. Envenio, Inc., a corporation organized under the laws of Canada.
6. JUUL Labs (Shanghai) Co., Ltd., a limited liability company organized under the laws of China.
7. JUUL Labs (Shanghai) Co., Ltd., Shenzhen Branch, a limited liability company organized under the laws of China.
8. JUUL Labs (Shanghai) Co., Ltd., Suzhou Branch, a limited liability company organized under the laws of China.
9. JUUL Labs and Products Israel, Ltd., a limited liability company organized under the laws of Israel.
10. JUUL Labs Austria GmbH, a limited liability company organized under the laws of Austria.
11. JUUL Labs Belgium SRL, a limited liability company organized under the laws of Belgium.
12. JUUL Labs Canada, Ltd., a limited liability company organized under the laws of Canada.

13. JUUL Labs Colombia S.A.S., a simplified stock company organized under the laws of Colombia.
14. JUUL Labs CZ & SK s.r.o., a company organized under the laws of the Czech Republic.
15. JUUL Labs Czech Republic s.r.o., a company organized under the laws of the Czech Republic.
16. JUUL Labs France SAS, a limited liability company organized under the laws of France.
17. JUUL Labs Germany GmbH, a limited liability company organized under the laws of Germany.
18. JUUL Labs Global Business Services, Sp. Z.o.o., a limited liability company organized under the laws of Poland.
19. JUUL Labs Greece M.E.P.E., a limited liability company organized under the laws of Greece.
20. JUUL Labs Exports, LLC, a limited liability company organized under the laws of Delaware.
21. JUUL Labs IHB FinCo Ltd., a limited liability company organized under the laws of England and Wales.
22. JUUL Labs IHB Limited, a limited liability company organized under the laws of England and Wales.
23. JUUL Labs India Private Limited, a private limited liability company organized under the laws of India.

24. JUUL Labs International Inc., a corporation organized under the laws of Delaware
25. JUUL Labs Ireland Ltd., a limited liability company organized under the laws of Ireland.
26. JUUL Labs Italia S.R.L., a limited liability company organized under the laws of Italy.
27. JUUL Labs Japan Company Limited, a company organized under the laws of Japan.
28. JUUL Labs Korea LLC, a limited liability company organized under the laws of Korea.
29. JUUL Labs Netherlands B.V., a private limited liability company organized under the laws of The Netherland.
30. JUUL Labs New Zealand Limited, a limited liability company organized under the laws of New Zealand.
31. JUUL Labs Poland, Sp. Z.o.o., a limited liability company organized under the laws of Poland.
32. JUUL Labs Portugal Unipessoal LDA, a private limited liability company organized under the laws of Portugal.
33. JUUL Labs RU Limited Liability Company, a limited liability company organized under the laws of Russia.
34. JUUL Labs Services, Sp. Z.o.o., a limited liability company organized under the laws of Poland.

35. JUUL Labs Singapore HoldCo Pte. Ltd, a limited liability company organized under the laws of Singapore.
36. JUUL Labs Spain S.L., a company organized under the laws of Spain.
37. JUUL Labs Switzerland GmbH, a limited liability company organized under the laws of Switzerland.
38. JUUL Labs UK Holdco Limited (DMCC Branch), a limited liability company organized under the laws of the United Arab Emirates.
39. JUUL Labs UK HoldCo Limited, a limited liability company organized under the laws of England and Wales.
40. JUUL Labs UK Ltd., a limited liability company organized under the laws of England and Wales.
41. JUUL Labs Ukraine, a limited liability company organized under the laws of Ukraine.
42. JUUL Labs Virginia, LLC, a limited liability company organized under the laws of Virginia.
43. JUUL Pasadena Labs, Inc., a corporation organized under the laws of Delaware.
44. Main Mission LLC, a limited liability company organized under the laws of Delaware.
45. Main Mission Mezz LLC, a limited liability company organized under the laws of Delaware.
46. Pax Labs, Inc., a corporation organized under the laws of Delaware.
47. Representative Office of JUUL Labs Singapore Holdco Pte. Ltd.

48. Shenzhen Wei'ai Tech Co., Ltd., a limited liability company organized under the laws of China.
49. Vapor Investment Partners LLC, a limited liability company organized under the laws of Delaware.
50. VMR CZ Sro, a company organized under the laws of Czech Republic.
51. VMR (HK) Holdings LTD, a limited liability company organized under the laws of Hong Kong.
52. VMR Products B.V. a company organized under the laws of the Netherlands.
53. VMR Products LLC, a limited liability company organized under the laws of Florida.
54. VMR Products Shenzhen Ltd., a limited liability company organized under the laws of China.
55. VMR Products, Inc., a corporation organized under the laws of Delaware.
56. VMR Strategic LLC, a limited liability company organized under the laws of Delaware.
57. Zhonghe Hengtong VMR (Shenzhen) Technology, Ltd., a limited liability company organized under the laws of China.